12:00 AM
 | 
Jun 09, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ecopipam: Phase IIb started

Psyadon began the double-blind, crossover, U.S. Phase IIb PSY302 trial to evaluate 50 and 100 mg ecopipam once daily in about 30 patients with Tourette's syndrome ages 7-17 years. Patients will receive either ecopipam or placebo for 4 weeks and...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >